新华医疗
(600587)
| 流通市值：83.05亿 | | | 总市值：83.05亿 |
| 流通股本：6.07亿 | | | 总股本：6.07亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,253,927,001.42 | 9,736,089,608.71 | 6,977,967,842.53 | 4,790,414,888.01 |
| 营业收入 | 2,253,927,001.42 | 9,736,089,608.71 | 6,977,967,842.53 | 4,790,414,888.01 |
| 二、营业总成本 | 2,091,993,896.87 | 9,132,053,228.23 | 6,517,556,689.17 | 4,397,550,992.73 |
| 营业成本 | 1,698,455,120.45 | 7,287,764,218.31 | 5,225,989,859.88 | 3,582,676,003.81 |
| 税金及附加 | 17,791,577.24 | 74,262,268.7 | 49,294,464.71 | 33,170,450.39 |
| 销售费用 | 201,528,998.28 | 894,025,276.17 | 627,531,352.26 | 387,744,638.85 |
| 管理费用 | 88,954,037.17 | 406,460,151.82 | 271,695,712.22 | 178,062,225.44 |
| 研发费用 | 74,912,128.31 | 442,028,622.51 | 321,747,889.75 | 201,713,769.93 |
| 财务费用 | 10,352,035.42 | 27,512,690.72 | 21,297,410.35 | 14,183,904.31 |
| 其中:利息费用 | 9,615,170.14 | 41,405,973.64 | 31,806,317.28 | 21,348,494.52 |
| 其中:利息收入 | 3,529,992.07 | 18,444,852.59 | 14,415,796.3 | -9,225,075.47 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -23,755,114.05 | 39,100,637.21 | 48,281,980.32 | 52,113,996.21 |
| 资产处置收益 | 135,530.86 | -993,363.98 | -894,616.82 | -837,997.31 |
| 资产减值损失(新) | -3,579,776.16 | -78,503,721.65 | -29,650,386.99 | -14,253,517.71 |
| 信用减值损失(新) | -4,130,802 | -45,085,082.26 | -10,999,083.71 | -11,340,053.6 |
| 其他收益 | 16,638,901.17 | 72,311,965.88 | 51,200,205.94 | 36,093,544.73 |
| 四、营业利润 | 147,241,844.37 | 590,866,815.68 | 518,349,252.1 | 454,639,867.6 |
| 加:营业外收入 | 2,243,081.77 | 8,173,114.34 | 4,374,699.97 | 2,699,995.21 |
| 减:营业外支出 | 358,278.15 | 7,919,402.97 | 4,268,154.53 | 2,862,993.27 |
| 五、利润总额 | 149,126,647.99 | 591,120,527.05 | 518,455,797.54 | 454,476,869.54 |
| 减:所得税费用 | 24,455,043 | 62,985,947.19 | 74,371,769.85 | 64,085,293.87 |
| 六、净利润 | 124,671,604.99 | 528,134,579.86 | 444,084,027.69 | 390,391,575.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 124,671,604.99 | 528,134,579.86 | 444,084,027.69 | 390,391,575.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 124,057,030.92 | 526,335,669.83 | 434,310,536.42 | 385,717,607.04 |
| 少数股东损益 | 614,574.07 | 1,798,910.03 | 9,773,491.27 | 4,673,968.63 |
| 扣除非经常损益后的净利润 | 113,681,063.03 | 457,025,924.12 | 370,403,619.54 | 332,742,127.52 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.2 | 0.87 | 0.72 | 0.64 |
| (二)稀释每股收益 | 0.2 | 0.87 | 0.72 | 0.64 |
| 八、其他综合收益 | - | -1,628,422.22 | -10,798,668.15 | -3,094,830.46 |
| 归属于母公司股东的其他综合收益 | - | -1,628,422.22 | -10,798,668.15 | -3,094,830.46 |
| 九、综合收益总额 | 124,671,604.99 | 526,506,157.64 | 433,285,359.54 | 387,296,745.21 |
| 归属于母公司股东的综合收益总额 | 124,057,030.92 | 524,707,247.61 | 423,511,868.27 | 382,622,776.58 |
| 归属于少数股东的综合收益总额 | 614,574.07 | 1,798,910.03 | 9,773,491.27 | 4,673,968.63 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |